Atlas Trials

Scynexis, Inc.

19 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Scynexis, Inc.

RecordFirmDate
ADME Study of [14^C]-Ibrexafungerp in Healthy Male Subjects (NCT05668429)Scynexis, Inc.2022-12-14
A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole (NCT05178862)Scynexis, Inc.2022-08-03
Safety of Pregnant Subjects Exposed to Ibrexafungerp Including Infant Outcomes (NCT05908682)Scynexis, Inc.2022-07-28
Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis (NCT05399641)Scynexis, Inc.2022-05-01
ADME Study of [14C]-Ibrexafungerp in Healthy Male Subjects (NCT04307082)Scynexis, Inc.2019-12-05
Study to Evaluate the Effect of SCY-078 (Ibrexafungerp) on the PK of Pravastatin in Healthy Subjects (NCT04092751)Scynexis, Inc.2019-11-22
Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC) (NCT04029116)Scynexis, Inc.2019-10-21
Study to Evaluate the Effect of SCY-078 on the PK of Dabigatran in Healthy Subjects (NCT04092725)Scynexis, Inc.2019-09-09
Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (NCT03987620)Scynexis, Inc.2019-06-07
Evaluate Safety and Efficacy of the Coadministration of Ibrexafungerp With Voriconazole in Patients With Invasive Pulmonary Aspergillosis (NCT03672292)Scynexis, Inc.2019-01-22
Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (VANISH 303) (NCT03734991)Scynexis, Inc.2019-01-04
Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris (CARES) (NCT03363841)Scynexis, Inc.2017-11-15

Track Scynexis, Inc. automatically

Every clearance here is in the API, with alerts when new ones post.